

Marco Merli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/39179/publications.pdf>

Version: 2024-02-01

48
papers

767
citations

687363

13
h-index

580821

25
g-index

48
all docs

48
docs citations

48
times ranked

2032
citing authors

#	ARTICLE	IF	CITATIONS
1	Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13735.	3.4	31
2	Superinfections caused by carbapenem-resistant Enterobacterales in hospitalized patients with COVID-19: a multicentre observational study from Italy (CREVID Study). <i>JAC-Antimicrobial Resistance</i> , 2022, 4, .	2.1	13
3	Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality. <i>Clinical Infectious Diseases</i> , 2021, 72, 1868-1869.	5.8	11
4	Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients. <i>Journal of Infection</i> , 2021, 82, 414-451.	3.3	8
5	Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 105-111.	6.0	55
6	Does interval time between liver transplant and COVID-19 infection make the difference?. <i>Digestive and Liver Disease</i> , 2021, 53, 169-170.	0.9	4
7	SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study. <i>BMC Infectious Diseases</i> , 2021, 21, 184.	2.9	25
8	Neurological manifestations in patients hospitalized with COVID-19: A retrospective analysis from a large cohort in Northern Italy. <i>European Journal of Neuroscience</i> , 2021, 53, 2912-2922.	2.6	22
9	COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study. <i>Gut</i> , 2021, 70, 1914-1924.	12.1	30
10	Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNeâ€”short- And long-term Immune reSponSe evALuation in health Care workErs. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2966-2979.	3.0	18
11	Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection. <i>Transplantation</i> , 2021, 105, e22-e24.	1.0	1
12	Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. <i>Journal of Infection</i> , 2020, 81, e11-e17.	3.3	102
13	Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study). <i>Clinical Microbiology and Infection</i> , 2020, 26, 1545-1553.	6.0	71
14	Quantification of 1,3â€”d â€”glucan by Wako Î²â€”glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study. <i>Mycoses</i> , 2020, 63, 1299-1310.	4.0	12
15	Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients. <i>PLoS ONE</i> , 2020, 15, e0236311.	2.5	92
16	Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. <i>Liver Transplantation</i> , 2020, 26, 1543-1544.	2.4	11
17	Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience. <i>American Journal of Transplantation</i> , 2020, 20, 2628-2629.	4.7	30
18	Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab. <i>Transplant Infectious Disease</i> , 2020, 22, e13334.	1.7	28

#	ARTICLE	IF	CITATIONS
19	Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy. PLoS ONE, 2020, 15, e0242765.	2.5	10
20	HIV-positive to HIV-positive liver transplantation: To be continued. Journal of Hepatology, 2019, 70, 788-789.	3.7	10
21	Risk factors for community-acquired bacterial meningitis: men who have sex with men (MSM) as a population at risk for meningococcal nasopharyngeal carriage. Infectious Diseases, 2019, 51, 714-717.	2.8	2
22	Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV. Transplant Infectious Disease, 2019, 21, e13165.	1.7	4
23	Post-surgical Hidden Costs: Infections. , 2019, , 127-139.		0
24	The impact of HIV infection and men who have sex with men status on hepatitis A infection: The experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009-2016 period. Journal of Viral Hepatitis, 2019, 26, 761-765.	2.0	7
25	Hepatitis A Virus in men who have sex with men: Need for awareness and vaccination. Liver International, 2018, 38, 581-584.	3.9	5
26	The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2018, 47, 95-103.	3.7	20
27	Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject. Aids, 2018, 32, 1727-1729.	2.2	2
28	<i>In vivo</i> evidence that the cannabinoid receptor 2-63 RR variant is associated with the acquisition and/or expansion of HIV infection. HIV Medicine, 2018, 19, 597-604.	2.2	4
29	Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. Journal of Hepatology, 2017, 67, 415-417.	3.7	7
30	NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B. Archives of Virology, 2017, 162, 2271-2277.	2.1	6
31	Systemic Inflammatory Response Is a Prognostic Marker in HIV-Infected Patients with Hepatocellular Carcinoma. Oncology, 2017, 93, 395-400.	1.9	11
32	Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients. BMC Infectious Diseases, 2017, 17, 723.	2.9	5
33	Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfecting patients. PLoS ONE, 2017, 12, e0181890.	2.5	10
34	Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients. PLoS ONE, 2017, 12, e0182007.	2.5	9
35	Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment. Viruses, 2016, 8, 91.	3.3	20
36	Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfecting patients with liver cirrhosis. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw492.	3.0	7

#	ARTICLE	IF	CITATIONS
37	Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir. <i>Medicine (United States)</i> , 2016, 95, e3780.	1.0	6
38	Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C. <i>Clinical Microbiology and Infection</i> , 2016, 22, 372-378.	6.0	15
39	Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients. <i>Clinical Microbiology and Infection</i> , 2016, 22, 386.e1-386.e3.	6.0	4
40	TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype. <i>World Journal of Gastroenterology</i> , 2016, 22, 8509.	3.3	9
41	Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin. <i>Medicine (United States)</i> , 2015, 94, e1876.	1.0	8
42	Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV) Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin: Table 1.. <i>Clinical Infectious Diseases</i> , 2015, 62, civ902.	5.8	1
43	Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman. <i>International Journal of Infectious Diseases</i> , 2014, 29, 100-102.	3.3	2
44	Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naïve individuals infected with hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1448-1450.	3.0	2
45	Noninvasive fibrosis biomarkers "APRI" and "Forns" are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs. <i>Liver International</i> , 2013, 33, 1113-1120.	3.9	10
46	COVID-19 in Liver Transplant Candidates: Pre- and Post-Transplant Outcome. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
47	Neurological Manifestations in Patients Hospitalized with COVID-19: A Retrospective Analysis from a Large Cohort in Northern Italy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
48	Predictors of Severe Respiratory Failure in Hospitalized Patients with SARS-CoV-2 Infection: Development and Validation of a Prediction Model (PREDI-CO Study). <i>SSRN Electronic Journal</i> , 0, , .	0.4	7